rug application for Linjeta™, its most advanced product candidate, has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier-stage product candidates include VIAtab™, a sublingual tablet formulation of insulin, a line of basal insulins and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at
www.biodel.com. Contact:The Trout Group LLCSeth D. Lewis, +1-646-378-2952Safe-Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for Linjeta(TM) and our other product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology, particularly Li
'/>"/>
SOURCE Biodel Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)2.
Dynatronics to Release Fourth Quarter and Year-End Results Wednesday, September 22, 2010; Conference Call Set for 1:00 p.m. ET3.
LightPath Technologies Announces Fourth Quarter and Fiscal 2010 Financial Results4.
Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder5.
Corgenix to Host Conference Call to Discuss Fiscal 2010 Results6.
Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule7.
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 20108.
Renhuang Schedules Conference Call to Discuss FY 2010 Third Quarter Results9.
Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference10.
Streamline Health® Solutions Reports Q2 Results11.
ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmins Potential to Transform the Treatment of Retinal Disorders